Phase I and Pharmacodynamic Study of the Oral MEK Inhibitor CI-1040 in Patients With Advanced Malignancies - Concepedia

Concepedia

Publication | Closed Access

Phase I and Pharmacodynamic Study of the Oral MEK Inhibitor CI-1040 in Patients With Advanced Malignancies

397

Citations

13

References

2005

Year

Patricia LoRusso, Alex A. Adjei, Mary Varterasian, Shirish M. Gadgeel, Joel M. Reid, David Mitchell, Lorelei J. Hanson, Pamela DeLuca, Laura M. Bruzek, Jill Piens,

Journal of Clinical Oncology

Abstract

CI-1040 was well tolerated at 800 mg BID administered with food. Both target suppression and antitumor activity were demonstrated in this phase I study.

References

	Year	Citations

Page 1